No black box warning on record for Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide

As of the latest FDA labeling reviewed, Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide (OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypotension: Correct volume or salt depletion prior to administration. ( 5.2 ) Monitor renal function and potassium in susceptible patients. Increased angina or myocardial infarction with calcium channel blockers may occur upon dosage initiation or increase ( 5.3 ). Observe for signs of fluid or electrolyte imbalance ( 5.6 ). Exacerbation or activation of systemic lupus

No black box warning on record for Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypotension: Correct volume or salt depletion prior to administration. ( 5.2 ) Monitor renal function and potassium in susceptible patients. Increased angina or myocardial infarction with calcium channel blockers may occur upon dosage initiation or increase ( 5.3 ). Observe for signs of fluid or electrolyte imbalance ( 5.6 ). Exacerbation or activation of systemic lupus

Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide Black Box Warning

No black box warning on record for Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide

Other warnings & precautions

Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide Black Box Warning

No black box warning on record for Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide

Other warnings & precautions